US 8278299
Pyrimidinediamine kinase inhibitors
granted A61KA61K31/5383A61K45/06
Quick answer
US patent 8278299 (Pyrimidinediamine kinase inhibitors) held by Rigel Pharmaceuticals, Inc. expires Mon Sep 27 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Oct 02 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 27 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 37
- CPC classes
- A61K, A61K31/5383, A61K45/06, A61P, A61P35/00